PRINTER'S NO. 1489
THE GENERAL ASSEMBLY OF PENNSYLVANIA
SENATE BILL
No.
1054
Session of
2018
INTRODUCED BY BROOKS, RESCHENTHALER, RAFFERTY, STEFANO AND WARD,
FEBRUARY 16, 2018
REFERRED TO HEALTH AND HUMAN SERVICES, FEBRUARY 16, 2018
AN ACT
Providing for licensure of buprenorphine office-based
prescribers; limiting the use of buprenorphine; and
establishing penalties.
The General Assembly of the Commonwealth of Pennsylvania
hereby enacts as follows:
Section 1. Short title.
This act shall be known and may be cited as the Buprenorphine
Medically Assisted Treatment Act.
Section 2. Definitions.
The following words and phrases when used in this act shall
have the meanings given to them in this section unless the
context clearly indicates otherwise:
"Buprenorphine." A material, compound, mixture of
preparation containing buprenorphine or its salts used as
medically assisted treatment for opioid addiction.
"Buprenorphine office-based prescriber." A person that is
assigned a waiver from the Drug Enforcement Administration,
including a special identification number, commonly referred to
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
as the "X" DEA number, and provides office-based prescribing of
buprenorphine.
"Department." The Department of Drug and Alcohol Programs of
the Commonwealth.
Section 3. Buprenorphine medically assisted treatment.
(a) Licensure.--The department shall establish a program for
licensure of buprenorphine office-based prescribers as qualified
by training and experience to prescribe buprenorphine.
(b) Fee.--A buprenorphine office-based prescriber shall pay
a fee of $10,000 for licensure by the department.
(c) Prohibition.--No buprenorphine office-based prescriber
shall prescribe buprenorphine to a patient unless all of the
following occur:
(1) The patient provides evidence demonstrating active
participation in an addiction treatment program licensed by
the department.
(2) The evidence of participation in the addiction
treatment program is documented in the patient's medical
record.
(3) The buprenorphine office-based prescriber is
licensed by the department as provided under subsection (a).
(d) Violations.--The State Board of Medicine shall
promulgate guidelines providing specific periods of license
suspension or revocation for a buprenorphine office-based
prescriber who dispenses or prescribes buprenorphine in
violation of this act.
Section 4. Effective date.
This act shall take effect in 60 days.
20180SB1054PN1489 - 2 -
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28